scholarly journals Role of gangliosides in prostate pathology

2016 ◽  
Vol 19 (1) ◽  
pp. 10-15
Author(s):  
Ilinca Nicolae ◽  
◽  
Corina-Daniela Ene ◽  
Simona Roxana Georgescu ◽  
◽  
...  

Molecular pathology of benign prostatic hyperplasia is multifactorial and involves endocrine, biochemical, immunological interactions. The mechanisms involved in the onset and progression of benign prostatic hyperplasia are: infections, 50 years of age, hormones and neurotransmitters imbalances, inflammation, oxidative stress. The potential role of glycosylation in the pathogenesis of prostate disease has been neglected. In this study we documented the profile of gangliosides in normal and pathological prostatic tissues together with the pathologic changes seen in the level of extracellular gangliosides in patients with prostate pathology. Analysis of the data in the literature suggests that gangliosides may represent immunologic markers useful in the differential diagnosis between prostate cancer and benign prostatic hyperplasia.

2014 ◽  
Vol 94 (3) ◽  
pp. 249-254 ◽  
Author(s):  
Paola Lucia Minciullo ◽  
Antonino Inferrera ◽  
Michele Navarra ◽  
Gioacchino Calapai ◽  
Carlo Magno ◽  
...  

Background: Several parameters including inflammatory mediators, hormones, dietary factors, inflammatory genes, and oxidative stress (OS) have been considered to play a role in the development of benign prostatic hyperplasia (BPH). Prostate tissue damage and OS may lead to compensatory cellular proliferation with resulting hyperplastic growth. Methods: We searched MEDLINE for articles in English published up to March 2014 using the key words ‘oxidative stress', ‘antioxidants' and ‘benign prostatic hyperplasia'. Results: Prostatic inflammation can cause the generation of free radicals. The extent of oxidative damage can be exacerbated by a decreased efficiency of antioxidant defense mechanisms. The balance between OS and the antioxidant component also has a role in developing prostate disease. Several works show the role of oxidant products and of depletion of antioxidant substances in BPH patients. It is accepted that free radicals play a role in carcinogenesis and that BPH should be considered a premalignant condition which may evolve into prostate cancer. High OS parameters and low antioxidant activity are more prominent in prostate cancer patients compared with BPH and controls. Conclusions: Further studies are needed to clarify the potential role of antioxidants in BPH also in view of preventing the progression to prostate cancer.


2020 ◽  
Vol 10 (2) ◽  
pp. 15-25
Author(s):  
Amrallah A. Mohammed ◽  
Hanna M. Ibrahim ◽  
Hanna A. Atwa ◽  
Ayman Elshentenawy ◽  
Amira Elwan

AbstractBackgroundDisturbance in cell cycle regulatory genes is a common finding among many types of cancers. The aim of this study is to evaluate the role of cyclin D1 and DJ-1 in benign prostatic hyperplasia (BPH) and prostate cancer (PC).MethodThe current study enclosed 40 patients diagnosed with PC and 40 cases of BPH. The expression level of cyclin D1 and DJ-1 were evaluated by immunohistochemistry (IHC). Cyclin D1 scored depending on the percentage of stained nuclear tumor cells. While scoring of DJ-1 was based on intensity. The results were correlated with clinicopathological features and outcome.ResultsIn the PC group, cyclin D1 was detected in 95% and overexpressed in 42.5%, DJ-1 was positively stained in 85% and overexpressed in 47.5%. Meanwhile, in the BPH group, cyclin D1 was not detected and DJ-1 stained in only 2.5%. There was a statistically significant difference in Gleason score (GS), tumor stage, size, and treatment failure (p =< 0.001). In the terms of PC diagnosis prediction, although cyclin D1 was more specific (100%), DJ-1 is more sensitive than cyclin D1 (80%, 70%, respectively) (p = 0.000).ConclusionsCyclin D1 and DJ-1 may emerge as a promising way for diagnosis of PC in certain circumstances, as the presence of insufficient tissue sampling, small foci of carcinoma or benign lesions mimic PC. This is in addition to the known role of cyclin D1 and DJ-1 in PC prognosis.


2016 ◽  
Vol 2 (1) ◽  
pp. 1-13
Author(s):  
Alexander V. Pechersky

AbstractOnce people reach 35-40 years, they have a decrease in their pool of pluripotent stem cells, and show a violation of tissue renewal, a decrease in the number of cell-producers of testosterone (Leidig cells) and a reduction in testosterone circulating in the blood. Partial androgen deficiency in aging men violates division and differentiation of androgen-dependent cells and increases the risk for development of benign prostatic hyperplasia and prostate cancer. The recovery of testosterone production and regeneration helps make a decrease in proliferative activity, and the rehabilitation of regulation of androgen-dependent cells of the prostate and other tissues and organs, as well as reduce insulin resistance among older men.


2016 ◽  
Vol 15 (1) ◽  
pp. 30-34
Author(s):  
Ilinca Nicolae ◽  
◽  
Corina-Daniela Ene ◽  
Mirela Petrescu ◽  
Simona Roxana Georgescu ◽  
...  

Molecular pathology of benign prostatic hyperplasia is multifactorial and involves endocrine, biochemical, immunological interactions. The mechanisms involved in the onset and progression of benign prostatic hyperplasia are: infections, older than 50 years, imbalances in hormones and neurotransmitters, inflammation, oxidative stress. It is estimated that an infectious etiology can be a cause of wrong immune response directed at the prostate. Inflammatory neuropathies often occur after infections with various microorganisms. It is also known, that the presence of microorganisms is heterogeneous in patients with benign prostatic hyperplasia. In this paper we documented the antibody profile of anti-GM1, -GM2, -GM3, -GD1a, -GD1b, -GT1b, -GQ1b IgG and IgM type in 30 patients with benign prostatic hyperplasia and in 30 controls. The results showed an increasing anti-GD1a and anti-GQ1b titer in patients with benign prostatic hyperplasia compared to control. The authors suggest that a careful monitoring of the patients developing an endogenous anti-gangliosidic immune response is required in order to assess these antibodies as potential risk factors for neuropathy in patients with benign prostatic hyperplasia.


1999 ◽  
pp. 209
Author(s):  
Patrik Finne ◽  
Hannu Koistinen ◽  
Wan-Ming Zhang ◽  
Anssi Auvinen ◽  
Riitta Koistinen ◽  
...  

2010 ◽  
Vol 85 (3) ◽  
pp. 328-333 ◽  
Author(s):  
Gianna Pace ◽  
Caterina Di Massimo ◽  
Daniela De Amicis ◽  
Carlo Corbacelli ◽  
Laura Di Renzo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document